Randomized trial of vitamin D versus placebo supplementation on markers of systemic inflammation in hypertensive patients.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Animal and cell models indicated that vitamin D modulates inflammatory activity, which is considered relevant in the pathogenesis of arterial hypertension and cardiovascular diseases.

The researchers therefore aimed to investigate the effect of vitamin D supplementation on systemic markers of inflammation in a cohort of hypertensive patients.

Why It Was Studied

ClinicalTrials.gov Identifier: NCT02136771; EudraCT No. 2009-018,125-70.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

What Was Measured

PubMed files the paper under topics including Austria, Biomarkers, Cholecalciferol, Dietary Supplements, Hypertension, Inflammation Mediators and Vitamin D.

Author keywords: Randomized controlled trial and Supplementation.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Nutrition, metabolism, and cardiovascular diseases : NMCD), a journal based in Netherlands.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.